Clinical trials: Relapsing Remitting MS
Multiple Sclerosis
Exploratory Study to Assess Clinical Response to Gilenya® (Fingolimod) in Hispanics With RRMS
Gilenya (fingolimod) is approved for multiple sclerosis. However, it is unclear of its clinical effect in the Hispanics with MS given that clinical studies had limited representation of this population.
- Trial name
- NCT01592097
- Where
- United States
- Volunteers
- 51 people
- Sponsor
- University of Southern California
Multiple Sclerosis, MS, Multiple Sclerosis
Transcranial Direct Current Stimulation for Fatigue, Mood, and Cognition in Multiple Sclerosis
Multiple sclerosis (MS) is a chronic, inflammatory and disabling disease of the Cnetral Nervous System characterized by relapsing and / or progressive somatosensory, motor and vestibular clinical manifestations.
- Conditions
- Multiple Sclerosis, MS, Multiple Sclerosis, Multiple Sclerosis (MS) - Relapsing-remitting, Multiple Sclerosis (MS) Primary Progressive
- Trial name
- NCT07680738
- Testing
- Transcranial Direct Current Stimulation
- Where
- Mexico
- Volunteers
- 38 people
- Sponsor
- Universidad de Almeria
Multiple Sclerosis, Multiple Sclerosis (MS) - Relapsing-remitting
Extracorporeal Shock Wave Therapy in Enhancing Sensitivity and Postural Stability in Multiple Sclerosis
This randomized controlled trial aimed to investigate the efficacy of Extracorporeal Shock Wave Therapy (ESWT) on plantar somatosensory function, knee joint proprioception, and spatiotemporal gait parameters in individuals…
- Conditions
- Multiple Sclerosis, Multiple Sclerosis (MS) - Relapsing-remitting, Sensorimotor Gait Disorder
- Trial name
- NCT07514104
- Testing
- Extracorporeal Shock Wave Therapy (ESWT)
- Where
- Turkey (Türkiye)
- Volunteers
- 54 people
- Sponsor
- Furkan Bilek
Relapsing-Remitting Multiple Sclerosis
Behavior and Activity Monitoring in MS
The investigators propose to conduct a randomized 6-month intervention study comparing cognitive functioning in individuals with relapsing-remitting multiple sclerosis assigned to either a physical activity or an active…
- Trial name
- NCT03244696
- Testing
- Step Tracking, Water Tracking
- Where
- United States
- Volunteers
- 87 people
- Sponsor
- Ohio State University
Relapsing-Remitting Multiple Sclerosis
Autologous T Cell Vaccine (TCV) for Multiple Sclerosis
This is a 1 year study to evaluate the efficacy, safety, and tolerability of Tovaxin T cell therapy in subjects with a clinically isolated syndrome (CIS) and relapse-remitting multiple sclerosis (RR-MS).
- Trial name
- TERMS (NCT00245622)
- Testing
- Tovaxin Autologous T cell vaccine
- Where
- 33 sites in United States
- Volunteers
- 150 people
- Sponsor
- Opexa Therapeutics, Inc.
Multiple Sclerosis
Long-term, Open-label, Multicenter Study Assessing Long-term Cardiovascular Risks
This study will evaluate if patients who had a serious cardiovascular event upon initiation of fingolimod are at risk to delevop long term other cardiovascular events
- Trial name
- NCT02232061
- Testing
- Fingolimod
- Where
- 4 sites in Belgium, Germany and 1 more
- Volunteers
- 6 people
- Sponsor
- Novartis Pharmaceuticals
Multiple Sclerosis, Remitting-Relapsing Multiple Sclerosis
Cognitive Performance, Sleep Disturbances and Fatigue in Multiple Sclerosis
Fatigue is a prevalent symptom in patients with multiple sclerosis (MS) and is associated with considerable impairment in quality of life as well as loss of occupational capacity.
- Conditions
- Multiple Sclerosis, Remitting-Relapsing Multiple Sclerosis, Primary Progressive Multiple Sclerosis, Secondary Progress Multiple Sclerosis
- Trial name
- NCT07426991
- Testing
- No Intervention: Observational Cohort
- Where
- 2 sites in Germany
- Volunteers
- 837 people, healthy volunteers welcome
- Sponsor
- Heinrich-Heine University, Duesseldorf
Multiple Sclerosis, Multiple Sclerosis (MS) - Relapsing-remitting
"Selfie" Videos: A Novel, Patient-centered, Comprehensive Approach to Measuring Function in MS
The goal of this observational study is to validate a novel, cost-effective method for real-world assessment using patient-acquired "selfie" videos in people with multiple sclerosis.
- Conditions
- Multiple Sclerosis, Multiple Sclerosis (MS) - Relapsing-remitting, Multiple Sclerosis (MS) Primary Progressive, MS (Multiple Sclerosis)
- Trial name
- NCT07222618
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- University of California, San Francisco
Multiple Sclerosis, Relapsing-Remitting
An Observational Study for the Assessment of Compliance and Persistence to Rebif® Therapy of Patients With Relapsing-remitting Multiple Sclerosis (MS) and Evaluation of Potential Factors Influencing These Parameters
The present study aims to assess the adherence to therapy with interferon beta-1a (Rebif®) and at investigating potential factors that are involved in its outcome, in a representative sample of patients with relapsing remitting…
- Trial name
- NCT01112345
- Where
- Greece
- Volunteers
- 133 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Multiple Sclerosis, Relapsing-Remitting
Examining Effects of Ocrevus on Cognitive Fatigue Using fMRI
The purpose of this research study is to investigate the effectiveness of MS Disease modifying medications on cognitive fatigue in persons with relapsing remitting multiple sclerosis (RRMS).
- Trial name
- NCT04448977
- Testing
- Ocrevus
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Kessler Foundation
Multiple Sclerosis, Multiple Sclerosis (MS) - Relapsing-remitting
The Effect of Virtual Reality on Fatigue and Functional Capacity in Patients With MS
This clinical trial aims to evaluate the effectiveness of virtual reality (VR) as a complementary intervention to traditional physical therapy for individuals diagnosed with Multiple Sclerosis (MS).
- Conditions
- Multiple Sclerosis, Multiple Sclerosis (MS) - Relapsing-remitting, Virtual Reality
- Trial name
- VRMS (NCT06987994)
- Testing
- control group( physical therapy), Experemental group
- Where
- Turkey (Türkiye)
- Volunteers
- 30 people
- Sponsor
- Istinye University
Multiple Sclerosis
Effects of Acthar on Recovery From Cognitive Relapses in MS
The purpose of this study is to evaluate the effect of a medication called Acthar on recovery from multiple sclerosis-related relapses that impact cognition.
- Trial name
- NCT02290444
- Testing
- Adrenocorticotropic Hormone
- Where
- United States
- Volunteers
- 64 people
- Sponsor
- State University of New York at Buffalo
Multiple Sclerosis, Relapsing-Remitting
Zenapax (Daclizumab) to Treat Relapsing Remitting Multiple Sclerosis
This study will examine the safety of Zenapax (daclizumab) in patients with multiple sclerosis (MS). MS is thought to be caused by an over-reactive immune response.
- Trial name
- NCT00071838
- Testing
- Daclizumab
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting
Clinnova-MS: A Prospective Cohort Study of Patients With Multiple Sclerosis (Switzerland)
This prospective cohort study is part of the Clinnova programme and aims to (i) identify clinical imaging and omics characteristics associated with early Multiple Sclerosis (MS) and with transitioning phases to progressive MS, as…
- Conditions
- Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Secondary Progressive
- Trial name
- NCT06526364
- Testing
- All participants will be asked to provide data and samples for collection and analysis.
- Where
- Switzerland
- Volunteers
- 100 people
- Sponsor
- University Hospital, Basel, Switzerland
Relapsing-remitting Multiple Sclerosis
Safety, Tolerability, Efficacy and Optimal Dose Finding Study of BAF312 in Patients With Relapsing-remitting Multiple Sclerosis
The purpose of this study was to determine the dose-response curve for the MRI-based efficacy of BAF312 compared with placebo in patients with Relapsing-Remitting Multiple Sclerosis (RRMS), and to characterize its safety and…
- Trial name
- NCT00879658
- Testing
- BAF312
- Where
- 72 sites in United States, Canada and 10 more
- Volunteers
- 297 people
- Sponsor
- Novartis Pharmaceuticals
Relapsing-Remitting Multiple Sclerosis
Implementation Study of Treatment Optimization Recommendations on Relapsing-Remitting Multiple Sclerosis (RR MS) Subjects
Brief Summary: 800 RRMS Subjects currently treated with Avonex or Copaxone will be randomized to either continue on their current therapy or receive Rebif therapy. The subjects will be followed for 2 years.
- Trial name
- NCT00101959
- Testing
- Rebif
- Sponsor
- EMD Serono
Multiple Sclerosis (MS) - Relapsing-remitting, Mediterranean Diet
Effect of Low Histamine-Based Modified Mediterranean Diet in Multiple Sclerosis
This randomized controlled trial will evaluate the effects of a low histamine-based modified Mediterranean diet in adults with relapsing-remitting multiple sclerosis (RRMS).
- Trial name
- HistaMed-MS (NCT07501520)
- Testing
- Low Histamine-Based Modified Mediterranean Diet, Traditional Mediterranean Diet
- Where
- Turkey (Türkiye)
- Volunteers
- 51 people
- Sponsor
- Firat University
Relapsing Remitting Multiple Sclerosis, Clinically Isolated Syndrome
Clinical Importance of Glucose Regulation in Relapsing MS
The purpose of this study is to assess the relationship of blood glucose levels in persons with Multiple Sclerosis (MS) who have experienced a relapse and will be receiving intravenous steroids for the relapse, to their recovery…
- Trial name
- NCT03004079
- Where
- United States
- Volunteers
- 160 people
- Sponsor
- University of Virginia
Multiple Sclerosis, Relapsing-Remitting, Adult ALL
Investigating the Effects of Hydroxyvitamin D3 on Multiple Sclerosis
Investigating the effects of hydroxyvitamin D3 on clinical, radiologic and immunomodulatory markers in MS patients: A randomized, clinical trial- a pilot study
- Conditions
- Multiple Sclerosis, Relapsing-Remitting, Adult ALL, Vitamin D3 Deficiency
- Trial name
- NCT05340985
- Testing
- 25(OH)D3, vitamin D3
- Volunteers
- 54 people
- Sponsor
- Tehran University of Medical Sciences
Relapsing-Remitting Multiple Sclerosis, Multiple Sclerosis
A Study Evaluating the Effectiveness of Tecfidera (Dimethyl Fumarate) on Multiple Sclerosis (MS) Disease Activity and Patient-Reported Outcomes
The primary objective of the study is to estimate the annualized relapse rate (ARR) in participants with Relapsing Remitting Multiple Sclerosis (RRMS) who are treated with dimethyl fumarate (DMF) over a 12-month period.
- Trial name
- PROTEC (NCT01930708)
- Testing
- dimethyl fumarate
- Where
- 90 sites in Austria, Belgium and 9 more
- Volunteers
- 1,114 people
- Sponsor
- Biogen